These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20726033)

  • 21. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.
    Farshidi D; Chiu MW
    J Am Acad Dermatol; 2010 Jan; 62(1):164-165. PubMed ID: 20082904
    [No Abstract]   [Full Text] [Related]  

  • 22. [HIV/HCV double infection: combination is a clear therapy option].
    Reich B
    Dtsch Med Wochenschr; 2004 Jul; 129(28-29):1590. PubMed ID: 15274242
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of liver iron in hepatitis C antiviral treatment.
    Musallam KM; Sharara AI; Inati A; Taher AT
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):769. PubMed ID: 20440118
    [No Abstract]   [Full Text] [Related]  

  • 24. Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients.
    Donato C; Cingolani A; Pinnetti C; De Luca A
    J Hepatol; 2010 Feb; 52(2):306-7. PubMed ID: 20006404
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment strategies of acute and chronic hepatitis C].
    Gładysz A; Inglot M
    Przegl Epidemiol; 2002; 56 Suppl 5():10-5. PubMed ID: 15553066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 27. [Hepatitis C].
    Pache I; Gonvers JJ
    Rev Med Suisse Romande; 2002 Oct; 122(10):507-12. PubMed ID: 12494784
    [No Abstract]   [Full Text] [Related]  

  • 28. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
    Mondelli MU
    Hepatology; 2014 Oct; 60(4):1126-9. PubMed ID: 24753082
    [No Abstract]   [Full Text] [Related]  

  • 29. [Healing hepatitis C infections. Pegylated interferon alfa-2a opens new perspectives].
    MMW Fortschr Med; 2003 Jun; 145(26):52-3. PubMed ID: 12916339
    [No Abstract]   [Full Text] [Related]  

  • 30. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy.
    Bolkhir A; Brunt EM; Solomon HS; Hayashi PH
    Liver Transpl; 2007 Feb; 13(2):309-11; author reply 312. PubMed ID: 17260390
    [No Abstract]   [Full Text] [Related]  

  • 32. High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
    Pockros P; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Chan A; Hill G
    Hepatology; 2008 Oct; 48(4):1349-50. PubMed ID: 18821613
    [No Abstract]   [Full Text] [Related]  

  • 33. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
    Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
    Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regression of low-grade non-Hodgkin's lymphoma after treatment with pegylated interferon plus ribavirin in hepatitis C virus infection.
    Mazzaro C; Spina M; Tirelli U
    J Clin Oncol; 2005 Jul; 23(19):4470-1; author reply 4471. PubMed ID: 15994165
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection.
    Bartlett JG
    Hopkins HIV Rep; 2005 May; 17(3):15. PubMed ID: 16419314
    [No Abstract]   [Full Text] [Related]  

  • 36. Optimal dosage of ribavirin.
    Mangia A; Andriulli A
    Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
    [No Abstract]   [Full Text] [Related]  

  • 37. Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin.
    Jimenez-Sousa MA; Almansa R; de la Fuente C; Caro-Paton A; Ruiz L; Sanchez-Antolín G; Gonzalez JM; Aller R; Alcaide N; Largo P; Resino S; de Lejarazu RO; Bermejo-Martin JF
    Eur Cytokine Netw; 2010 Jun; 21(2):84-91. PubMed ID: 20483710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Assessment and monitoring of patients with chronic hepatitis C on antiviral therapy--state of the art in 2003].
    Simon K; Szymczak A
    Pol Arch Med Wewn; 2004 Jul; 112(1):891-8. PubMed ID: 15526854
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis C drug development at a crossroads.
    Nelson DR
    Hepatology; 2009 Oct; 50(4):997-9. PubMed ID: 19787813
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute exacerbation among chronic hepatitis C patients: tip of the iceberg that deserves more attention.
    Wong RJ; Cheung RC
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1181-2. PubMed ID: 23735449
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.